MICHAEL WAINSCOTT: Open Payments
NPI 1326412552 · FLORENCE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$468 in 29 payments from 10 companies in 2025. Trend: 2023 $237 · 2024 $328 · 2025 $468
Food & beverage: $468
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $280 |
| Gilead Sciences, Inc. | 2 | $36 |
| Novo Nordisk Inc | 2 | $29 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $26 |
| GlaxoSmithKline, LLC. | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| ABIOMED | 1 | $16 |
| Exact Sciences Corporation | 1 | $15 |
| Merck Sharp & Dohme LLC | 1 | $14 |
Products named: VRAYLAR, MAVYRET, Kerendia, TRELEGY ELLIPTA, HETLIOZ, Auvelity, Ozempic, Cologuard Collection Kit.
Industry payments across KY — which companies pay providers there.
